Repository logo
 

Distinct and targetable role of calcium-sensing receptor in leukaemia.

Published version
Peer-reviewed

Repository DOI


Change log

Authors

Kumar, Rahul 
Cais, Alessia 
Paulini, Lara 
Kahler, Alisa 

Abstract

Haematopoietic stem cells (HSC) reside in the bone marrow microenvironment (BMM), where they respond to extracellular calcium [eCa2+] via the G-protein coupled calcium-sensing receptor (CaSR). Here we show that a calcium gradient exists in this BMM, and that [eCa2+] and response to [eCa2+] differ between leukaemias. CaSR influences the location of MLL-AF9+ acute myeloid leukaemia (AML) cells within this niche and differentially impacts MLL-AF9+ AML versus BCR-ABL1+ leukaemias. Deficiency of CaSR reduces AML leukaemic stem cells (LSC) 6.5-fold. CaSR interacts with filamin A, a crosslinker of actin filaments, affects stemness-associated factors and modulates pERK, β-catenin and c-MYC signaling and intracellular levels of [Ca2+] in MLL-AF9+ AML cells. Combination treatment of cytarabine plus CaSR-inhibition in various models may be superior to cytarabine alone. Our studies suggest CaSR to be a differential and targetable factor in leukaemia progression influencing self-renewal of AML LSC via [eCa2+] cues from the BMM.

Description

Acknowledgements: This work was supported by grant 70113903 to D.S.K. from the Deutsche Krebshilfe. We thank the Quantitative Proteomics Unit (Institute of Biochemistry II, Goethe University Frankfurt) for support on LC-MS instrumentation and the DFG for funding the Orbitrap Lumos LC-MS system used in this study (FuG 403765277). D.N. is an endowed professor of the German José-Carreras-Foundation (DJCLSH03/01).

Keywords

Humans, Receptors, Calcium-Sensing, Proto-Oncogene Proteins c-myc, Calcium, Oncogene Proteins, Fusion, Signal Transduction, Leukemia, Myeloid, Acute, Cytarabine, Tumor Microenvironment

Journal Title

Nat Commun

Conference Name

Journal ISSN

2041-1723
2041-1723

Volume Title

14

Publisher

Springer Science and Business Media LLC
Sponsorship
Cancer Research UK (DRCRPG-Nov22/100014)